Pineal parenchymal tumor of intermediate differentiation: Treatment outcomes of five cases

Watanabe,Tsubasa; Mizowaki,Takashi; Arakawa,Yoshiki; Iizuka,Yusuke; Ogura,Kengo; Sakanaka,Katsuyuki; Miyamoto,Susumu; Hiraoka,Masahiro

doi:10.3892/mco.2013.231

Pineal parenchymal tumor of intermediate differentiation: Treatment outcomes of five cases

Authors:
- Tsubasa Watanabe
- Takashi Mizowaki
- Yoshiki Arakawa
- Yusuke Iizuka
- Kengo Ogura
- Katsuyuki Sakanaka
- Susumu Miyamoto
- Masahiro Hiraoka
View Affiliations

Affiliations: Department of Radiation Oncology and Image‑Applied Therapy, Kyoto University Graduate School of Medicine, Shogoin, Sakyo‑ku, Kyoto 606‑8507, Japan, Department of Neurosurgery, Kyoto University Graduate School of Medicine, Shogoin, Sakyo‑ku, Kyoto 606‑8507, Japan
Published online on: December 23, 2013 https://doi.org/10.3892/mco.2013.231
Pages: 197-202

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pineal parenchymal tumor of intermediate differentiation (PPTID) is a rare disease, first classified by the World Health Organization in 2000. The number of available studies on the treatment of PPTID is currrently limited and the optimal management for this disease has not yet been determined. We retrospectively evaluated the treatment outcomes for PPTID at our institute and analyzed the roles of radiation therapy and chemotherapy for this disease. The clinical data on five patients diagnosed with PPTID since 2000 were retrospectively reviewed. patients with cerebrospinal dissemination at diagnosis received biopsy‑only surgery, craniospinal and whole‑ventricular irradiation and chemotherapy. Patients with locally limited disease at diagnosis received local or whole‑ventricular irradiation after surgery. The median relapse‑free and overall survival were 72.9 and 94.1 months, respectively. Two of the five patients developed a relapse of cerebrospinal dissemination after treatment and succumbed to the disease. All the patients who received both craniospinal and whole‑ventricular irradiation exhibited evidence of cerebral white matter abnormalities in magnetic resonance imaging and developed neurocognitive disorders after treatment. Although PPTID may be aggressive and has cerebrospinal fluid seeding potential, PPTID patients may survive long‑term, even after recurrence. Considering the long survival time and the late adverse effects due to intensive treatment, the irradiation field and usage of chemotherapy after surgery require optimization.

View Figures

View References

1	Schild SE, Scheithauer BW, Schomberg PJ, Hook CC, Kelly PJ, Frick L, Robinow JS and Buskirk SJ: Pineal parenchymal tumors. Clinical, pathologic, and therapeutic aspects. Cancer. 72:870–880. 1993. View Article : Google Scholar : PubMed/NCBI
2	Jouvet A, Saint-Pierre G, Fauchon F, Privat K, Bouffet E, Ruchoux MM, Chauveinc L and Fèvre-Montange M: Pineal parenchymal tumors: a correlation of histological features with prognosis in 66 cases. Brain Pathol. 10:49–60. 2000. View Article : Google Scholar : PubMed/NCBI
3	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
4	Clark AJ, Ivan ME, Sughrue ME, Yang I, Aranda D, Han SJ, Kane AJ and Parsa AT: Tumor control after surgery and radiotherapy for pineocytoma. J Neurosurg. 113:319–324. 2010. View Article : Google Scholar : PubMed/NCBI
5	Clark AJ, Sughrue ME, Ivan ME, Aranda D, Rutkowski MJ, Kane AJ, Chang S and Parsa AT: Factors influencing overall survival rates for patients with pineocytoma. J Neurooncol. 100:255–260. 2010. View Article : Google Scholar : PubMed/NCBI
6	Fangusaro J, Finlay J, Sposto R, Ji L, Saly M, Zacharoulis S, Asgharzadeh S, Abromowitch M, Olshefski R, Halpern S, Dubowy R, Comito M, Diez B, Kellie S, Hukin J, Rosenblum M, Dunkel I, Miller DC, Allen J and Gardner S: Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. Pediatr Blood Cancer. 50:312–318. 2008.
7	Jouvet A, Fèvre-Montange M, Besançon R, Derrington E, Saint-Pierre G, Belin MF, Pialat J and Lapras C: Structural and ultrastructural characteristics of human pineal gland, and pineal parenchymal tumors. Acta Neuropathol. 88:334–348. 1994. View Article : Google Scholar : PubMed/NCBI
8	Fauchon F, Jouvet A, Paquis P, Saint-Pierre G, Mottolese C, Ben Hassel M, Chauveinc L, Sichez JP, Philippon J, Schlienger M and Bouffet E: Parenchymal pineal tumors: a clinicopathological study of 76 cases. Int J Radiat Oncol Biol Phys. 46:959–968. 2000. View Article : Google Scholar : PubMed/NCBI
9	Maarouf M, El Majdoub F, Bührle C, Voges J, Lehrke R, Kocher M, Hunsche S, Treuer H and Sturm V: Pineal parenchymal tumors. Management with interstitial iodine-125 radiosurgery. Strahlenther Onkol. 186:127–134. 2010. View Article : Google Scholar : PubMed/NCBI
10	Stoiber EM, Schaible B, Herfarth K, Schulz-Ertner D, Huber PE, Debus J and Oertel S: Long term outcome of adolescent and adult patients with pineal parenchymal tumors treated with fractionated radiotherapy between 1982 and 2003 - a single institution’s experience. Radiat Oncol. 5:1222010.PubMed/NCBI
11	Lutterbach J, Fauchon F, Schild SE, Chang SM, Pagenstecher A, Volk B, Ostertag C, Momm F and Jouvet A: Malignant pineal parenchymal tumors in adult patients: patterns of care and prognostic factors. Neurosurgery. 51:44–55. 2002. View Article : Google Scholar : PubMed/NCBI
12	Schild SE, Scheithauer BW, Haddock MG, Wong WW, Lyons MK, Marks LB, Norman MG and Burger PC: Histologically confirmed pineal tumors and other germ cell tumors of the brain. Cancer. 78:2564–2571. 1996. View Article : Google Scholar : PubMed/NCBI
13	Aoki T, Takahashi JA, Ueba T, Oya N, Hiraoka M, Matsui K, Fukui T, Nakashima Y, Ishikawa M and Hashimoto N: Phase II study of nimustine, carboplatin, vincristine, and interferon-β with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group. J Neurosurg. 105:385–391. 2006.PubMed/NCBI
14	Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G and Needles MN: Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 11:850–856. 1993.
15	Packer RJ, Sutton LN, Elterman R, et al: Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 81:690–698. 1994. View Article : Google Scholar : PubMed/NCBI
16	Wakabayashi T, Hatano N, Kajita Y, Yoshida T, Mizuno M, Taniguchi K, Ohno T, Nagasaka T and Yoshida J: Initial and maintenance combination treatment with interferon-beta, MCNU (ranimustine), and radiotherapy for patients with previously untreated malignant glioma. J Neurooncol. 49:57–62. 2000. View Article : Google Scholar : PubMed/NCBI
17	Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M and Yoshida J: IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 65:7573–7579. 2005.PubMed/NCBI
18	Kurisaka M, Arisawa M, Mori T, Sakamoto T, Seike M, Mori K, Okada T, Wakiguchi H and Kurashige T: Combination chemotherapy (cisplatin, vinblastin) and low-dose irradiation in the treatment of pineal parenchymal cell tumors. Childs Nerv Syst. 14:564–569. 1998. View Article : Google Scholar : PubMed/NCBI
19	Hinkes BG, von Hoff K, Deinlein F, Warmuth-Metz M, Soerensen N, Timmermann B, Mittler U, Urban C, Bode U, Pietsch T, Schlegel PG, Kortmann RD, Kuehl J and Rutkowski S: Childhood pineoblastoma: experiences from the prospective multicenter trials HIT-SKK87, HIT-SKK92 and HIT91. J Neurooncol. 81:217–223. 2007. View Article : Google Scholar : PubMed/NCBI
20	Li G, Mitra S, Karamchandani J, Edwards MS and Wong AJ: Pineal parenchymal tumor of intermediate differentiation: clinicopathological report and analysis of epidermal growth factor receptor variant III expression. Neurosurgery. 66:963–968. 2010. View Article : Google Scholar
21	Crossen JR, Garwood D, Glatstein E and Neuwelt EA: Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol. 12:627–642. 1994.PubMed/NCBI
22	Monje ML, Mizumatsu S, Fike JR and Palmer TD: Irradiation induces neural precursor-cell dysfunction. Nat Med. 8:955–962. 2002. View Article : Google Scholar : PubMed/NCBI
23	Mizumatsu S, Monje ML, Morhardt DR, Rola R, Palmer TD and Fike JR: Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res. 63:4021–4027. 2003.PubMed/NCBI
24	Redmond KJ, Mahone EM, Terezakis S, Ishaq O, Ford E, McNutt T, Kleinberg L, Cohen KJ, Wharam M and Horska A: Association between radiation dose to neuronal progenitor cell niches and temporal lobes and performance on neuropsychological testing in children: a prospective study. Neuro Oncol. 15:360–369. 2013. View Article : Google Scholar
25	Gong X, Schwartz PH, Linskey ME and Bota DA: Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology. 76:1126–1134. 2011. View Article : Google Scholar : PubMed/NCBI
26	Brown WR, Blair RM, Moody DM, Thore CR, Ahmed S, Robbins ME and Wheeler KT: Capillary loss precedes the cognitive impairment induced by fractionated whole-brain irradiation: a potential rat model of vascular dementia. J Neurol Sci. 257:67–71. 2007. View Article : Google Scholar : PubMed/NCBI